Stockscreener 앱 받기
116.80
4.32%
-5.27
시간 외 거래:
116.80
전일 마감가:
$122.07
열려 있는:
$123.99
하루 거래량:
384.80K
Relative Volume:
0.59
시가총액:
$4.88B
수익:
-
순이익/손실:
-
주가수익비율:
-124.26
EPS:
-0.94
순현금흐름:
-
1주 성능:
-4.99%
1개월 성능:
+27.39%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$116.56
$125.20
1주일 범위
$116.56
$131.24
52주 변동 폭
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
명칭
Veradermics Inc
전화
228.372.3376
주소
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
116.80 | 5.10B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-03-02 | 개시 | Citigroup | Buy |
| 2026-03-02 | 개시 | Jefferies | Buy |
| 2026-03-02 | 개시 | Leerink Partners | Outperform |
Veradermics Inc 주식(MANE)의 최신 뉴스
Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom - BioSpace
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Index - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Value Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 2000 Growth Benchmark - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000E Growth Benchmark - marketscreener.com
2026 Power 25 Healthcare: Dr. Reid Waldman - Hartford Business Journal
Veradermics, Incorporated(NYSE: MANE) added to Russell Small Cap Completeness Index - marketscreener.com
Veradermics, Incorporated(NYSE: MANE) added to Russell 3000E Index - marketscreener.com
Veradermics, Incorporated Actuals & Estimates (NYSE:MANE) - TradingView
Cantor Fitzgerald reiterates Veradermics stock rating after CEO dinner By Investing.com - Investing.com Australia
MANE Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Veradermics stock rating after CEO dinner - Investing.com
MANE Stock Pops As Traders Hunt Biotech Momentum - StocksToTrade
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Veradermics, Incorporated(NYSE: MANE) added to S&P Global BMI Index - marketscreener.com
Veradermics, Incorporated(NYSE:MANE) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now? - Yahoo Finance
MANEVeradermics Inc Forecast, Target Price - Finviz
Veradermics Incorporated (MANE) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
BHVN,MANE Forecast, Target Price - Finviz
Analysts Offer Insights on NA Companies: Sunbelt Rentals Holdings Inc (SUNB), Veradermics, Incorporated (MANE) and JBS (JBS) - The Globe and Mail
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $138 - Moomoo
LifeSci Capital Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $135 - Moomoo
Veradermics Company Profile & Introduction - Moomoo
MANE: Extended-release oral minoxidil shows promise for rapid, consistent hair growth in large, underserved markets - TradingView
Total liabilities of Veradermics, Incorporated – BX:MANE - TradingView
Number of shareholders of Veradermics, Incorporated – BX:MANE - TradingView
MANE Technical Analysis | Trend, Signals & Chart Patterns | VERADERMICS INC (NYSE:MANE) - ChartMill
Hot Picks: Biotech rebound driven by innovation and drug pipelines - BNN Bloomberg
Veradermics (MANE) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Needham Initiates Veradermics(MANE.US) With Buy Rating, Announces Target Price $136 - Moomoo
Two biotech leaders join Achieve Life's new quitting drug push - Stock Titan
This New Hair-Loss Drug Could Be the Biggest Breakthrough in Decades - Cosmopolitan
Veradermics to Present at Upcoming June 2026 Investor Conferences - BioSpace
Veradermics to Present at Upcoming June Investor Conferences - Business Wire
Veradermics to Present VDPHL01 Phase 2/3 ‘302’ Study Results at 2026 World Congress for Hair Research - geneonline.com
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research - BioSpace
Veradermics to present hair loss drug trial data on Friday - Investing.com
Veradermics to present hair loss drug trial data on Friday By Investing.com - Investing.com Canada
New oral drug shows success in reversing hair loss - Fast Company
10 Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts - Yahoo Finance
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
Veradermics Is Maintained at Buy by Citigroup - Moomoo
Veradermics Price Target Raised to $135.00/Share From $120.00 by Citigroup - Moomoo
SR ONE CAPITAL MANAGEMENT, LP's Veradermics Inc(MANE) Holding History - GuruFocus
Citi Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $135 - Moomoo
Viking Global-affiliates hold 1.69M Veradermics shares (MANE) - Stock Titan
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO - Yahoo Finance
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $138 - Moomoo
Veradermics Inc (MANE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veradermics Inc 주식 (MANE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Feb 05 '26 |
Buy |
37.99 |
96,200 |
3,655,079 |
489,932 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Feb 06 '26 |
Buy |
36.34 |
30,521 |
1,109,056 |
520,453 |
| Coric Vlad | Director |
Feb 05 '26 |
Buy |
17.00 |
117,646 |
1,999,982 |
319,398 |
| CHILDS JOHN W | Director |
Feb 05 '26 |
Buy |
17.00 |
294,117 |
4,999,989 |
2,202,006 |
| Longitude Capital Partners V, | 10% Owner |
Feb 05 '26 |
Buy |
17.00 |
1,075,000 |
18,275,000 |
2,600,399 |
| ENRIGHT PATRICK G | Director |
Feb 05 '26 |
Buy |
17.00 |
1,075,000 |
18,275,000 |
2,600,399 |
1.17%
2.48%
자본화:
|
볼륨(24시간):